Dr. Jennifer Buell is the President and Chief Executive Officer at MiNK Therapeutics. She brings more than 25 years of biopharmaceutical experience, leading teams to advance discovery candidates through to clinical development to commercialization. She was previously President and Chief Operating Officer at Agenus, where she was responsible for organizational operations, overseeing research, clinical development, manufacturing, commercial operations, investor relations and external affairs. During her tenure, she transformed Agenus from a neoantigen vaccine company to a global, fully-integrated biotech company with multiple strategic partnerships. Prior to Agenus, Dr. Buell held leadership positions in R&D operations at Bristol-Myers Squibb and Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government-sponsored clinical programs. She obtained her PhD in Cellular, Biochemical, and Molecular Biochemistry with an MS in Biostatistics from Tufts University.

© 2024 BioFutureTM. All Rights Reserved

Produced by